The salmeterol/fluticasone propionate combination 50/100 μg b.i.d is effective as initial maintenance therapy in mild and moderate asthmatics

M. L. Lange, K. W. House, C. A. Scott, T. P. Shah, M. L. M. Akveld (Research Triangle Park, United States Of America; Uxbridge, United Kingdom)

Source: Annual Congress 2001 - Combination of long-acting B2-agonists and corticosteroids in obstructive airways disease
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. L. Lange, K. W. House, C. A. Scott, T. P. Shah, M. L. M. Akveld (Research Triangle Park, United States Of America; Uxbridge, United Kingdom). The salmeterol/fluticasone propionate combination 50/100 μg b.i.d is effective as initial maintenance therapy in mild and moderate asthmatics. Eur Respir J 2001; 16: Suppl. 31, 1253

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Comparison of once-daily ciclesonide 160 μg versus twice-daily fluticasone propionate 88 μg in children with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 711s
Year: 2006

Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Superior efficacy of the salmeterol/fluticasone 50/100 mcg combination compared to fluticasone 200 mcg in children with uncontrolled asthma – the VIAPAED trial
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004

Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010